Injection site pruritus: FDA reporting patterns
65,676 FDA FAERS reports mention Injection site pruritus. 9,297 reports have a serious outcome flag.
Medicines named as suspect
- Etanercept: 22,081 reports
- Adalimumab: 10,263 reports
- Dupilumab: 6,082 reports
- Tirzepatide: 2,884 reports
- Exenatide: 2,074 reports
- Hydroxyprogesterone: 1,862 reports
- Glatiramer: 1,687 reports
- Dulaglutide: 1,207 reports
- Evolocumab: 953 reports
- Sarilumab: 832 reports
- Galcanezumab: 803 reports
- Ixekizumab: 789 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.